Literature DB >> 17309516

Carnitine deficiency provokes cisplatin-induced hepatotoxicity in rats.

Abdulhakeem A Al-Majed1.   

Abstract

This study investigates whether or not carnitine deficiency is a risk factor and could contribute to cisplatin-induced liver toxicity. A total of 60 adult male Wistar albino rats were divided into six groups. The first three groups were injected intraperitoneally with normal saline, propionyl-l-carnitine (500 mg/kg), and d-carnitine (500 mg/kg), respectively, for 10 successive days. The fourth, fifth and sixth groups were injected intraperitoneally with the same doses of normal saline, propionyl-l-carnitine and d-carnitine, respectively, for 5 successive days before and after a single dose of cisplatin (7 mg/kg). Administration of the standard nephrotoxic dose of cisplatin did not produce any changes in serum alanine transaminase and gamma-glutamyl transferase and no morphological changes in liver tissues. However, it did produce a significant increase in thiobarbituric acid reactive substances and total nitrate/nitrite and a significant decrease in reduced glutathione content in liver tissues. On the other hand, combined treatment with cisplatin and d-carnitine induced a dramatic increase in serum alanine transaminase and gamma-glutamyl transferase, as well as progressive reduction in total carnitine and ATP content in liver tissue. Moreover, histopathological examination of liver tissues confirmed the biochemical data, where cisplatin and d-carnitine combination showed signs of liver injury manifested as focal necro-inflammatory changes and portal inflammation. Interestingly, in carnitine supplemented rats using propionyl-l-carnitine, cisplatin did not produce any biochemical and histopathological changes in liver tissues. In conclusion, data from this study suggest for the first time that (1) carnitine deficiency is a risk factor and could precipitate cisplatin-induced hepatotoxicity, (2) oxidative stress is not the main cause of cisplatin-related hepatotoxicity and (3) propionyl-l-carnitine prevents the development of cisplatin-induced liver injury.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17309516     DOI: 10.1111/j.1742-7843.2006.00024.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  13 in total

Review 1.  A review on the role of L-carnitine in the management of tamoxifen side effects in treated women with breast cancer.

Authors:  Nahla E El-Ashmawy; Rania M Khalil
Journal:  Tumour Biol       Date:  2013-12-12

2.  Dose-dependent protective effect of L-carnitine on oxidative stress in the livers of hyperthyroid rats.

Authors:  Serap Yildirim; Abdulkadir Yildirim; Senol Dane; Elvin Aliyev; Ramazan Yigitoglu
Journal:  Eurasian J Med       Date:  2013-02

3.  Protective effects of melatonin and L-carnitine against methotrexate-induced toxicity in isolated rat hepatocytes.

Authors:  Lamiaa A Khatab; Ihab T Abdel-Raheem; Asser I Ghoneim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-11-25       Impact factor: 3.000

4.  Progression of diethylnitrosamine-induced hepatic carcinogenesis in carnitine-depleted rats.

Authors:  Salim S Al-Rejaie; Abdulaziz M Aleisa; Abdulaziz A Al-Yahya; Saleh A Bakheet; Abdulmalik Alsheikh; Amal G Fatani; Othman A Al-Shabanah; Mohamed M Sayed-Ahmed
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

5.  Carnitine deficiency and oxidative stress provoke cardiotoxicity in an ifosfamide-induced Fanconi Syndrome rat model.

Authors:  Mohamed M Sayed-Ahmed; Amal Q Darweesh; Amal J Fatani
Journal:  Oxid Med Cell Longev       Date:  2010 Jul-Aug       Impact factor: 6.543

6.  Preparation of CoS nanoparticles-cisplatin bio-conjugates and investigation of their effects on SH-SY5Y neuroblastoma cell line.

Authors:  Muhammed Sait Ertugrul; Hayrunnisa Nadaroglu; Ozge Balpinar Nalci; Ahmet Hacimuftuoglu; Azize Alayli
Journal:  Cytotechnology       Date:  2020-10-23       Impact factor: 2.058

7.  Role of carnitine in cancer chemotherapy-induced multiple organ toxicity.

Authors:  Mohamed M Sayed-Ahmed
Journal:  Saudi Pharm J       Date:  2010-08-05       Impact factor: 4.330

Review 8.  Cisplatin in cancer therapy: molecular mechanisms of action.

Authors:  Shaloam Dasari; Paul Bernard Tchounwou
Journal:  Eur J Pharmacol       Date:  2014-07-21       Impact factor: 4.432

9.  4-Hydroxyhalcone effects on cisplatin-induced genotoxicity model.

Authors:  Aref Nazari; Mina Mirian; Mahmoud Aghaei; Mehdi Aliomrani
Journal:  Toxicol Res (Camb)       Date:  2021-01-05       Impact factor: 3.524

10.  Effect of infliximab against cisplatin-induced nephrotoxicity.

Authors:  Erkan Cure; Aynur Kirbas; Levent Tumkaya; Medine C Cure; Osman Z Sahin; Yildiray Kalkan; Suleyman Yuce; Durdu Altuner
Journal:  Saudi Med J       Date:  2014-09       Impact factor: 1.484

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.